Evidence map›Paper›PMID 33667102›Full record

ArticleJournal of natural products2021

Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity.

Janis Fricke, Alexander M Sherwood, Adam L Halberstadt, Robert B Kargbo, Dirk Hoffmeister

Open access · greenAbstract read
In one paragraph

Article in Journal of natural products, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. In Vitro Psilocybin Synthesis by Co-Immobilized Enzymes.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Article
  4. Article
  5. Interpol Review of Drug Analysis 2019-2022.Forensic science international. Synergy · 2023
    Review
  6. Review
  7. Enlightening the "Spirit Molecule": Photomodulation of the 5-HTAngewandte Chemie (International ed. in English) · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Janis FrickeDepartment Pharmaceutical Microbiology at the Hans-Knöll-Institute, Friedrich-Schiller-Universität Jena, Winzerlaer Strasse 2, 07745 Jena, Germany.
Alexander M SherwoodUsona Institute, Madison Wisconsin 53711, United States.ORCID 0000-0003-0895-0791
Adam L HalberstadtDepartment of Psychiatry, University of California San Diego, La Jolla, California 92093-0804, United States.ORCID 0000-0001-5096-5829
Robert B KargboUsona Institute, Madison Wisconsin 53711, United States.
Dirk HoffmeisterDepartment Pharmaceutical Microbiology at the Hans-Knöll-Institute, Friedrich-Schiller-Universität Jena, Winzerlaer Strasse 2, 07745 Jena, Germany.ORCID 0000-0002-5302-6461
Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. - Hans-Knöll-Institut (HKI) · DEUsona Institute · USUniversity of California San Diego · US

Funding

The Next Generation of Hallucinogens: A New Class of Synthetic Psychoactive DrugsR01DA041336 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HALBERSTADT, ADAM L. · 2017 to 2020
$1.4M
NIDA NIH HHS R01 DA041336
6 · The paper itself

Abstract

A novel analogue of psilocybin was produced by hybrid chemoenzymatic synthesis in sufficient quantity to enable bioassay. Utilizing purified 4-hydroxytryptamine kinase from

Indexed as

AnimalsHallucinogensMiceMolecular StructurePsilocybePsilocybinTryptaminesHallucinogensPsilocybinTryptamines

Identifiers

PMID33667102
PMCPMC9191645
OpenAlexW3133617718

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.